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Editorial to the article “Blood transfusionpromotes cancer progression: A 
critical role for aged erythrocytes” by Atzil S. et al. MS 200712047 
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Allogeneic red blood cell (RBC) transfusions are associated with increased mortality 
1, major adverse cardiac and non-cardiac outcome 2, and low output failure in cardiac 
surgery. Transfusion of allogeneic RBC transfusions has also been found to be an 
independent factor increasing mortality in trauma including patients with traumatic 
brain injury 3, burns 4, liver transplantation, intensive care medicine 5 and the 
treatment of acute coronary syndrome 6. In addition, allogeneic RBC, fresh frozen 
plasma and platelet transfusions result in a several fold increase in postoperative and 
nosocomial infections 6,7. Furthermore, allogeneic RBC, fresh frozen plasma and 
platelet transfusions frequently cause transfusion related acute lung injury 6,8 which in 
itself again increases mortality, morbidity and costs. Last but not least, costs of RBC 
transfusions have been significantly underestimated even when excluding the cost of 
treatment of these adverse outcomes or the prolonged intensive care and hospital 
stay related to RBC transfusion 9. 
In the current issue of the Journal, Atzil and co-workers alert us of another, potentially 
harmful effect of RBC transfusions, namely the potential to promote tumor growth. In 
an established rat model of tumor growth, Atzil and co-workers demonstrate that 
transfusion of (the equivalent of) autologous and allogeneic RBCs increases lung 
retention of tumor cells several fold 10. Interestingly, they could show that this effect is 
directly linked to the transfused RBCs and not related to the co-administration of 
leukocytes or soluble factors of the supernatant. The magnitude of tumor growth 
promotion was found to be dependent on storage duration with RBC stored for >9 
days having a significantly more pronounced deleterious effect.  
The reason for cancer progression after blood transfusion is unclear and the paper by 
Atzil et al. did not precisely elucidate the mechanism(s) involved. The perioperative 
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period is characterized by numerous processes that can induce abrupt elevation of 
risk factors for the outbreak of preexisting micro-metastases and the seeding of new 
metastases. Here, deterioration of RBCs as a result of storage is demonstrated as a 
major cause for the cancer promoting effect. Atzil et al. mainly discuss the role of 
cellular immunity, particularly T cells and natural killer cells in controlling minimal 
residual tumor disease. It is hypothesized that transfused RBC become targets to 
host immunocytes. These deteriorated RBCs will outnumber circulating tumor cells 
and host immunocytes, after RBC transfusion may have a dramatically reduced 
chance to interact with residual tumor cells and eliminate them. 
Non-immune mechanisms may play an additional role in promoting cancer 
progression due to RBC transfusion. Importantly, acute and chronic hypoxia might be 
cause (anemia due to tumor-related blood loss) or consequence (quality of red blood 
cells) of blood transfusion and may lead to different biology within a tumor. Therefore, 
blood transfusion may have a promoting effect on cancer progression, given many 
hypoxia-induced signaling responses, including transcription factor hypoxia inducible 
factor 1 for angiogenesis, cell invasion, cell metabolism and cell survival 11. 
Interestingly, Tsai and co-workers 12 have recently shown that exchange transfusion 
with stored RBCs in their hamster window model reduced microvascular flow and 
functional capillary density by over 50 percent of the level achieved with fresh RBCs. 
Moreover, tissue oxygen levels were 3.5 and 14.4 mmHg for stored and fresh RBCs. 
It is thus conceivable that the transfusion of stored RBCs may induce tissue hypoxia 
also in tumor tissue and, by consequence, result in tumor growth progression via the 
above non-immune signaling pathways triggered by tissue hypoxia 11. Further 
research is urgently needed to understand these mechanisms better and to improve 
patient treatment in the future. 
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The clinical epidemiological and randomized trial evidence relating to transfusion 
being implicated in tumor recurrence remains controversial, but no reports suggest 
transfusions are beneficial in this respect. Animal data as presented by Atzil et al 10, 
although not directly transferable to humans, further supports a precautionary 
approach to blood transfusion.  
Considering all the above major adverse sequelae of allogeneic RBC transfusions 
several questions need to be asked: Firstly, do the benefits of allogeneic RBC 
transfusion outweigh these negative aspects? Secondly, what are our responsibilities 
towards the patient, or what is the patient’s role? Thirdly, are we aware of the key 
factors determining the exposure of patients to RBC transfusions? Forthly, and most 
importantly, how can we drastically and sustainably reduce the use of allogeneic 
RBC transfusion and improve the overall patient outcome? With recent evidence that 
the age of storage is also a factor adversely impacting on efficacy and adverse 
outcomes, the case for avoiding or minimizing transfusion grows stronger. 
The benefit of allogeneic RBC transfusion has been shown in preterm infants 13 and 
a benefit is presumed in massive bleeding due to trauma or surgery. Other (surgical) 
areas of benefit are unknown to these authors. 
What should be the patient’s role in deciding whether they are prepared to have a 
blood transfusion when alternatives are available? From a legal perspective if there 
was not a medical indication for a blood transfusion and a patient sustained an 
adverse outcome, the law is quite clear. A patient with an adverse outcome taking 
legal action against a doctor who did not warn about these risks and offer transfusion 
alternatives would have a strong case to present to the court. Such a case would be 
decided on the balance of probabilities, the plaintiff only needing to convince a court 
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that the alleged negligent act (the avoidable transfusion) was associated with the 
injurious outcome with a probability of i.e. >50% chance of being causative, and 
would not have occurred in the absence of the blood transfusion. This is different 
from the scientific uses of probability definitions where the probability threshold 
scientific method demands is >95%. A strong case can be supported that all patients 
receiving or likely to receive a blood transfusion should be informed of risks of an 
adverse outcome beyond those that are traditionally included in informed consent. 
What are the key factors determining the exposure of patients to RBC transfusions? 
The most significant predictors of allogeneic RBC transfusions are a low preoperative 
RBC mass or hemoglobin level, high perioperative surgical RBC loss and the hospital 
where a patient is being treated 14. Being aware of these simple facts allows 
designing a pragmatic solution, namely Patient Blood Management.  
Patient Blood Management comprises 3 main elements: (1) Correction of a low 
preoperative RBC mass or preoperative anemia, (2) minimizing perioperative RBC 
loss and (3) using minimal (i.e. low) hemoglobin based transfusion triggers. In the 
presence of clinical uncertainty the default position has been to administer a blood 
transfusion, this is not usually the case with other therapies. Blood transfusion is an 
inherently hazardous and costly therapy that should only be prescribed when there is 
evidence for patient benefit outweighing the potential for harm. The accumulating 
evidence for allogeneic blood transfusion being implicated as a risk factor for poorer 
clinical outcomes challenges this medical dogma demanding a more precautionary 
approach. 
Preoperative anemia is frequent in elective orthopedic surgery (20-35%) 15, cardiac 
surgery (25-37%) 2, gastro-intestinal surgery (up to 75%) and increases with age. A 
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high percentage of these anemic patients can be treated preoperatively with 
(intravenous) iron and erythropoietin 15. Perioperative blood loss can be reduced with 
blood sparing surgical techniques 16, maintenance of normothermia, low central 
venous pressure in liver surgery, cell salvage and re-transfusion, the use of anti-
fibrinolytics 17 and the avoidance of factor XIII deficiency in cancer surgery 18. Low 
hemoglobin based transfusion triggers are well tolerated even by high risk patients 
including those with sever coronary artery disease 16. 
Therefore, Patient Blood Management is neither science fiction nor rocket science. 
Patient Blood Management is possible today and needs to be implemented urgently 
in our hospitals. The hypothesis is allowed and justified that Patient Blood 
Management will decrease the use of allogeneic RBC transfusions, its cost and 
adverse sequelae significantly. 
The Department of Health of the Government of Western Australia recently 
acknowledged Patient Blood Management as an evidence-based patient-focused 
medical and surgical concept, being in full compliance with the Australian Council on 
Healthcare Standards, and decided to implement it as a standard of care statewide 
between 2008 and 2012. The decision of the executives of the Western Australian 
public health system to support the paradigm shift from behavior based transfusion 
practice to Patient Blood Management is based on whole series of reasons. The 
main ones can be grouped into five major categories: (1) Ethics: Informed consent 
over Patient Blood Management combined with the foremost principle ‘primum non 
nocere’ leads to new preferences not only for patients but also for physicians. (2) 
Evidence based medicine: The growing knowledge of transfusion limitations and 
adverse outcomes demands discontinuation of un-reflected transfusion habits and 
prescription routines. (3) Economics: True costs of RBC transfusions are currently 
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estimated to be two to four times the product costs or up to 5% of Western Australia’s 
total public healthcare budget. (4) Demographics: Blood shortages are to be 
expected due to an over-ageing population, actual and potential donor deferrals, loss 
of altruism and wide variations in transfusion practice. (5) Legal aspects: In 
developed countries during the Acquired Immunodeficiency Syndrome crisis, high-
ranking health officials were criminally indicted for blood safety concerns and charged 
with poisoning, manslaughter, professional negligence leading to death, inflicting 
bodily harm and even murder 19. In civil cases and out-of-court settlements, 
payments in compensation to victims in Ireland reached volumes equaling 15-20 
times the purchasing volume of the annual national blood supply.  
The Government of Western Australia therefore is to be congratulated for realizing 
the urgency of the matter and their subsequent decision to sustainably implement 
Patient Blood Management. By their decision and initiative they are leading the world 
in the battle against unnecessary RBC transfusions and its burden – financially and 
in terms of morbidity and mortality. 
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